Dennis Podlesak
Venture Capitalist @ Domain Associates
New York, United States
Dennis Podlesak is a Series A investor at Domain Associates in New York focused on Biotechnology and Pharmaceutical. Dennis Podlesak is the Co-Founder & Chairman at Transposon Therapeutics.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 60%
Last updated:
For AI agents: llms.txt
Industries Dennis Podlesak invests in
Stages Dennis Podlesak invests in
Countries Dennis Podlesak invests in
Investment Focus
Industry
- Biotechnology 2 (40%)
- Pharmaceutical 2 (40%)
- Hospital 1 (20%)
- Insurance 1 (20%)
- Health Care 1 (20%)
Stage
- Series A 2 (40%)
- Series B 1 (20%)
- Funding Round 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
RightCare Solutions
|
RightCare Solutions employs evidence-based technology to help healthcare providers optimize their discharge planning process. With their proprietary Discharge Decision Support System, D2S2, hospitals, insurers, and homecare agencies improve the quality of care for patients while alleviating the devastating toll that 30-day re-admissions exact onthe healthcare system. It was founded in 2011 and headquartered in Horsham, Pennsylvania. | Series B / Nov 13, 2013 | |
|
RightCare Solutions
|
RightCare Solutions employs evidence-based technology to help healthcare providers optimize their discharge planning process. With their proprietary Discharge Decision Support System, D2S2, hospitals, insurers, and homecare agencies improve the quality of care for patients while alleviating the devastating toll that 30-day re-admissions exact onthe healthcare system. It was founded in 2011 and headquartered in Horsham, Pennsylvania. | Series A / Oct 10, 2012 | |
Kalidex Pharmaceuticals
|
Kalidex Pharmaceuticals, Inc. manufactures pharmaceuticals. The company was incorporated in 2010 and is based in Menlo Park, California. | Jan 01, 2012 | |
Syndax Pharmaceuticals
|
Syndax Pharmaceuticals is a clinical-stage pharmaceutical company that focuses on an HDAC inhibitor for solid tumors and hematological tumors. It offers therapies to treat solid tumors and lung, breast, and hematological cancer. The company is developing axatilimab, a monoclonal antibody that blocks the colony-stimulating factor 1 (CSF-1) receptor,in development for chronic Graft versus Host Disease, and entinostat, a class I HDAC inhibitor.Syndax Pharmaceuticals pipeline includes and SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, in development for the treatment of patients with MLLr and NPM1 acute leukemias. | $9M / Series A / Mar 16, 2010 | |
|
Syndax Pharmaceuticals
|
Syndax Pharmaceuticals is a clinical-stage pharmaceutical company that focuses on an HDAC inhibitor for solid tumors and hematological tumors. It offers therapies to treat solid tumors and lung, breast, and hematological cancer. The company is developing axatilimab, a monoclonal antibody that blocks the colony-stimulating factor 1 (CSF-1) receptor,in development for chronic Graft versus Host Disease, and entinostat, a class I HDAC inhibitor.Syndax Pharmaceuticals pipeline includes and SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, in development for the treatment of patients with MLLr and NPM1 acute leukemias. | $40M / Series A / Apr 03, 2007 |
Co-Investors
About Domain Associates
Founded in 1985, Domain Associates, L.L.C. is a venture capital firm with an exclusive focus on life sciences. With $2 billion of capital under management, Domain is headquartered in Princeton, NJ with a second office in San Diego, CA.Domain’s three major investment segments are pharmaceuticals, specialty pharmaceuticals, and medical devices,while additional areas of interest include biomaterials, bioinstrumentation, and diagnostics. The Partners of Domain have a total of close to 200 person-years of experience among them in the healthcare/venture capital industries and have been involved in the formation and growth of more than 200 life-sciences companies. The highly focused network, experience, and reputation of this team have made it one of the top private-equity groups participating in the healthcare field.
Domain Associates Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Brian Dovey
Partner
|
|||
Brian Halak
Partner
|
|||
|
Dennis Podlesak
Venture Capitalist
|
|||
Eckard Weber
Partner
|
|||
Jesse I. Treu
Founding Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Dennis Podlesak invest in?
Dennis Podlesak invests primarily in Biotechnology, Pharmaceutical and Hospital startups, most often at Series A and Series B stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Dennis Podlesak last invest?
The most recent investment recorded for Dennis Podlesak closed in Nov 2013. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
